| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Share Option | (1) | 07/24/2029 | Ordinary Shares | 23,000 | (1) | D | |
| Share Option | (2) | 07/15/2030 | Ordinary Shares | 7,350 | (2) | D | |
| Share Option | (3) | 07/03/2031 | Ordinary Shares | 17,500 | (3) | D | |
| Share Option | (4) | 07/03/2031 | Ordinary Shares | 17,500 | (4) | D | |
| Share Option | (5) | 08/03/2032 | Ordinary Shares | 20,000 | (5) | D | |
| Share Option | (6) | 08/03/2032 | Ordinary Shares | 20,000 | (6) | D | |
| Share Option | (7) | 06/30/2033 | Ordinary Shares | 20,000 | (7) | D | |
| Share Option | (8) | 06/30/2033 | Ordinary Shares | 20,000 | (8) | D | |
| Share Option | (9) | 06/22/2034 | Ordinary Shares | 100,000 | $2.62 | D | |
| Share Option | (10) | 06/22/2034 | Ordinary Shares | 65,000 | $2.62 | D | |
| Share Option | (11) | 04/11/2035 | Ordinary Shares | 200,000 | $1.47 | D | |
| Explanation of Responses: |
| 1. Represents options to purchase ordinary shares at a price per share of 12.40 Euros granted on May 14, 2019 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 24, 2019. The options vest in three equal installments on each of the first three anniversaries of the date of grant. |
| 2. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods. |
| 3. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vest in three equal installments on each of the first three anniversaries of the date of grant. |
| 4. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods. |
| 5. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vest in three equal installments on each of the first three anniversaries of the date of grant. |
| 6. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods. |
| 7. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vest in three equal installments on each of the first three anniversaries of the date of grant. |
| 8. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods. |
| 9. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vest in three equal installments on each of the first three anniversaries of the date of grant. |
| 10. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the performance periods. |
| 11. Represents options to purchase ordinary shares at a price per share of $1.47 granted on March 26, 2025 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on April 11, 2025. The options vest in three equal installments on each of the first three anniversaries of the date of grant. |
| Remarks: |
| Executive Vice President of Corporate Development and General Counsel |
| /s/ Mark Busch, as attorney-in-fact for Joseph Sollee | 04/13/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||